Cyrus Calosing

937 total citations
21 papers, 739 citations indexed

About

Cyrus Calosing is a scholar working on Molecular Biology, Virology and Immunology. According to data from OpenAlex, Cyrus Calosing has authored 21 papers receiving a total of 739 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Virology and 7 papers in Immunology. Recurrent topics in Cyrus Calosing's work include Protein Degradation and Inhibitors (10 papers), HIV Research and Treatment (7 papers) and Histone Deacetylase Inhibitors Research (6 papers). Cyrus Calosing is often cited by papers focused on Protein Degradation and Inhibitors (10 papers), HIV Research and Treatment (7 papers) and Histone Deacetylase Inhibitors Research (6 papers). Cyrus Calosing collaborates with scholars based in United States, Germany and Canada. Cyrus Calosing's co-authors include Lynn Pulliam, Hans Rempel, Bing Sun, Jong Youl Kim, Masahito Kawabori, Christine L. Hsieh, Midori A. Yenari, Mary C. Nakamura, Rachid Kacimi and Tiina M. Kauppinen and has published in prestigious journals such as Journal of Neuroscience, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Cyrus Calosing

21 papers receiving 730 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cyrus Calosing United States	11	341	291	223	167	64	21	739
Richard Tawadros United States	7	219 0.6×	262 0.9×	228 1.0×	344 2.1×	132 2.1×	8	925
Rashed M. Nagra United States	15	514 1.5×	189 0.6×	291 1.3×	104 0.6×	92 1.4×	19	1.1k
Armelle Le Campion France	15	534 1.6×	103 0.4×	226 1.0×	41 0.2×	51 0.8×	20	1.1k
Alexander J. Gill United States	15	73 0.2×	180 0.6×	157 0.7×	267 1.6×	109 1.7×	20	569
O. Perrella Italy	15	262 0.8×	111 0.4×	87 0.4×	133 0.8×	180 2.8×	45	871
Jessica N. Hodge United States	9	162 0.5×	54 0.2×	96 0.4×	161 1.0×	129 2.0×	9	581
Amy Narvaez United States	6	401 1.2×	183 0.6×	200 0.9×	610 3.7×	324 5.1×	7	1.1k
Karen Nahmod United States	14	287 0.8×	39 0.1×	221 1.0×	39 0.2×	64 1.0×	28	695
Jennifer Chou United States	5	231 0.7×	55 0.2×	85 0.4×	42 0.3×	41 0.6×	6	445
Amy Paulino United States	10	35 0.1×	115 0.4×	119 0.5×	60 0.4×	123 1.9×	12	677

Countries citing papers authored by Cyrus Calosing

Since Specialization

Citations

This map shows the geographic impact of Cyrus Calosing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cyrus Calosing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cyrus Calosing more than expected).

Fields of papers citing papers by Cyrus Calosing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cyrus Calosing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cyrus Calosing. The network helps show where Cyrus Calosing may publish in the future.

Co-authorship network of co-authors of Cyrus Calosing

This figure shows the co-authorship network connecting the top 25 collaborators of Cyrus Calosing. A scholar is included among the top collaborators of Cyrus Calosing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cyrus Calosing. Cyrus Calosing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kharenko, Olesya A., Reena G. Patel, Cyrus Calosing, & Edward H. van der Horst. (2021). Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer. Cancer Gene Therapy. 29(6). 859–869. 20 indexed citations

Calosing, Cyrus, et al.. (2021). Synthesis of NVS-BPTF-1 and evaluation of its biological activity. Bioorganic & Medicinal Chemistry Letters. 47. 128208–128208. 8 indexed citations

Kharenko, Olesya A., Reena Patel, & Cyrus Calosing. (2021). Abstract 1129: Combination of ZEN-3694 with talazoparib is a novel therapeutic approach in ER positive breast cancer resistant to CDK4/6 inhibitors, independent of BRCA status. Cancer Research. 81(13_Supplement). 1129–1129. 1 indexed citations

Attwell, Sarah, et al.. (2018). Abstract P3-06-07: The BET bromodomain inhibitors ZEN-3694 and ZEN-3309 targets several mechanisms of resistance to endocrine therapies in preclinical models of ER+ breast cancers. Cancer Research. 78(4_Supplement). P3–6. 2 indexed citations

Kharenko, Olesya A., Reena G. Patel, S. David Brown, et al.. (2018). Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine. Journal of Medicinal Chemistry. 61(18). 8202–8211. 34 indexed citations

Wong, Norman C.W., Ewelina Kulikowski, Cyrus Calosing, et al.. (2017). APABETALONE (RVX-208) LOWERS CARDIOVASCULAR DISEASE (CVD) IN DIABETES MELLITUS BY A MECHANISM INVOLVING MICROBIOME MEDIATED ACTIVITY ON THE COMPLEMENT PATHWAY. Journal of the American College of Cardiology. 69(11). 2009–2009. 1 indexed citations

Wasiak, Sylwia, Dean Gilham, Laura Tsujikawa, et al.. (2017). Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208). Journal of Cardiovascular Translational Research. 10(4). 337–347. 43 indexed citations

Tsujikawa, Laura, Karen Norek, Cyrus Calosing, et al.. (2017). Abstract LB-038: Preclinical development and clinical validation of a whole blood pharmacodynamic marker assay for the BET bromodomain inhibitor ZEN-3694 in metastatic castration-resistant prostate cancer (mCRPC) patients. Cancer Research. 77(13_Supplement). LB–38. 8 indexed citations

Attwell, Sarah, Karen Norek, Cyrus Calosing, et al.. (2016). The investigational drug ZEN-3694, a novel BET-bromodomain inhibitor, inhibits multiple tumor immune escape mechanisms and has the potential to combine with immunotherapies. European Journal of Cancer. 69. S88–S88. 2 indexed citations

10.

Kulikowski, Ewelina, Sylwia Wasiak, Dean Gilham, et al.. (2016). Apabetalone (RVX-208) decreases atherogenic, thrombotic and inflammatory mediators in vitro and in plasma of patients with cardiovascular disease (CVD).. Atherosclerosis. 252. e245–e245. 2 indexed citations

11.

Kawabori, Masahito, Rachid Kacimi, Tiina M. Kauppinen, et al.. (2015). Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Deficiency Attenuates Phagocytic Activities of Microglia and Exacerbates Ischemic Damage in Experimental Stroke. Journal of Neuroscience. 35(8). 3384–3396. 287 indexed citations

12.

Attwell, Sarah, Eric Campeau, Ravi Jahagirdar, et al.. (2015). Abstract C86: The clinical candidate ZEN-3694, a novel BET bromodomain inhibitor, is efficacious in the treatment of a variety of solid tumor and hematological malignancies, alone or in combination with several standard of care and targeted therapies. Molecular Cancer Therapeutics. 14(12_Supplement_2). C86–C86. 8 indexed citations

13.

Pulliam, Lynn, Cyrus Calosing, Bing Sun, Carl Grünfeld, & Hans Rempel. (2014). Monocyte Activation from Interferon-α in HIV Infection Increases Acetylated LDL Uptake and ROS Production. Journal of Interferon & Cytokine Research. 34(10). 822–828. 15 indexed citations

14.

Kawabori, Masahito, Rachid Kacimi, Tiina M. Kauppinen, et al.. (2014). Abstract 9: Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) deficiency Attenuates Phagocytic Activities of Microglia and Exacerbates Ischemic Damage in Experimental Stroke. Stroke. 45(suppl_1). 1 indexed citations

15.

Rempel, Hans, Bing Sun, Cyrus Calosing, et al.. (2013). Monocyte Activation in HIV/HCV Coinfection Correlates with Cognitive Impairment. PLoS ONE. 8(2). e55776–e55776. 27 indexed citations

16.

Kawabori, Masahito, Masaaki Hokari, Zhen Zheng, et al.. (2013). Triggering Receptor Expressed on Myeloid Cells-2 Correlates to Hypothermic Neuroprotection in Ischemic Stroke. Therapeutic Hypothermia and Temperature Management. 3(4). 189–198. 30 indexed citations

17.

Pulliam, Lynn, Hans Rempel, Bing Sun, et al.. (2011). A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations. AIDS. 25(14). 1721–1726. 26 indexed citations

18.

Rempel, Hans, Bing Sun, Cyrus Calosing, Satish K. Pillai, & Lynn Pulliam. (2010). Interferon-α drives monocyte gene expression in chronic unsuppressed HIV-1 infection. AIDS. 24(10). 1415–1423. 56 indexed citations

19.

Sun, Bing, Linda Abadjian, Hans Rempel, et al.. (2010). Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy–treated subjects with human immunodeficiency virus type 1 infection. Journal of NeuroVirology. 16(2). 115–124. 36 indexed citations

20.

Rempel, Hans, Cyrus Calosing, Bing Sun, & Lynn Pulliam. (2008). Sialoadhesin Expressed on IFN-Induced Monocytes Binds HIV-1 and Enhances Infectivity. PLoS ONE. 3(4). e1967–e1967. 125 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact